ReviewHuman genomics2022
Preimplantation genetic testing for aneuploidy: challenges in clinical practice.
Review in Human genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Aneuploidy Patterns and Chaotic Embryos in IVF: Age-Stratified Analysis and Re-Biopsy Outcomes from a Romanian Cohort.Medicina (Kaunas, Lithuania) · 2026Article
- PGT-A in POSEIDON Patients - perspectives and limitations.JBRA assisted reproduction · 2025Article
- Review
- Article
- Differences in the EarlyJournal of cardiovascular development and disease · 2025Article
- Changes in sequencing technology used for preimplantation genetic testing for aneuploidy.Journal of assisted reproduction and genetics · 2025Review
- Assisted Reproductive Technology: A Ray of Hope for Infertility.ACS omega · 2025Review
- Article
- [Effect of Preimplantation Genetic Testing for Aneuploidies on Live Birth Outcomes and the Influencing Factors in Women of Advanced Maternal Age].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Article
- Non-Obstructive Azoospermia and Intracytoplasmic Sperm Injection: Unveiling the Chances of Success and Possible Consequences for Offspring.Journal of clinical medicine · 2024Review
- Advancements and Applications of Preimplantation Genetic Testing in In Vitro Fertilization: A Comprehensive Review.Cureus · 2024Review
- Should non-invasive prenatal testing be recommended for patients who achieve pregnancy with PGT?BMC pregnancy and childbirth · 2024Article
- Embryo drop-out rates in preimplantation genetic testing for aneuploidy (PGT-A): a retrospective data analysis from the DoLoRes study.Journal of assisted reproduction and genetics · 2024Article
- Using preimplantation genetic testing for monogenic disease for preventing citrullinemia type 1 transmission.Frontiers in genetics · 2024Article
- Novel embryo selection strategies-finding the right balance.Frontiers in reproductive health · 2023Article
- Fluid biopsies forMedicine internationalReview
- From the Understanding of Maternal Molecules and Mechanisms to Predicting Embryonic Development.Reproductive medicine and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Preimplantation genetic testing for aneuploidy (PGT-A) has been used widely during in vitro fertilization procedures in assisted reproductive centers throughout the world. Despite its wide use, concerns arise from the use of PGT-A technology in clinical decision-making. We address knowledge gaps in PGT-A, summarizing major challenges and current professional guidelines. First, PGT-A is a screening test and not a diagnostic test. Second, mosaicism is much higher in the blastocyst stage from PGT-A than had been recognized previously and a mosaic embryo may not accurately represent the genetic disease risk for future fetal disorders. Third, PGT-A was not validated clinically before use in patients; the best use of this technology for selected age-groups remains uncertain. Given these gaps, we believe that current professional policies relying on industry-self-regulation are insufficient. In the USA, the Food and Drug Administration may be the most appropriate agency to provide more definitive guidelines and regulations that are needed for better practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.